Library Search
-
Stanford Biotech Strategies Seminar. Seminar Summaries of Speakers Elaine Levin and Lawrence Sung, Ph.D. of Preston Gates & Ellis. ( January 2004 )
Elaine Levin gave an overview of problems facing small biotech companies. Lawrence Sung, Ph.D., provided an update on inventorship/ ownership considerations and the common law “research use” exemption. -
Stanford Biotech Strategies Seminar. Seminar Summaries of Speakers Michael Shuster and Lynn Pasahow of Fenwick & West. ( January 2004 )
Michael Shuster spoke on protecting early stage technology. Lynn Pasahow presented an update on biotech patent litigation with a special focus on selected recent cases. -
The Value of "Research Tool" Patents in View of Integra v. Merck ( July 2003 )
On June 6, 2003, the Court of Appeals for the Federal Circuit breathed new life into research tool patents when it held that the use of patented peptides for drug discovery was not exempt from infringement under the “safe harbor†provision of 35 U.S.C. § 271(e)(1). -
Patent Term Extensions and Restoration under the Hatch-Waxman Act ( November 2002 )
A utility patent confers the right to exclude others from making, using, offering to sell, or selling an invention in the United States. The patent term measures the time period in which a patent holder may exercise patent rights. During a patent's exclusivity period, the patent owner(s) may capitalize on the patent in a variety of ways including manufacturing, marketing, licensing, or selling an invention. -
Waxman-Hatch Law: What's Better For The Nation's Public Health, More Research Or Cheaper Generic Drugs? ( September 2000 )
The United States Patent Laws grant to a patentee the right to prevent others from. -
The FDA Alert--October 1999 ( October 1999 )
On August 6, 1999, the Food and Drug Administration (FDA) proposed to amend its current regulations governing the 180-day market exclusivity that is granted to certain generic drug products. This proposed rule represents a significant change to the current landscape of drug exclusivity. -
Drug Price Competition and Patent Term Restoration Act ( March 1999 )
Publication from the Food and Drug Administration which explains Title II of the Drug Price Competition and Patent Term Restoration Act under which certain patent holders have the opportunity to extend the terms of certain patents.
Ads by FindLaw